Used in the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) and immunoglobulin A nephropathy (IgAN). It works by neutralizing APRIL (a proliferation-inducing ligand), a protein involved in B-cell activation and survival. By blocking APRIL, the antibody reduces the production of autoantibodies and pathogenic immunoglobulins, particularly IgA, which play key roles in inflammation and tissue damage in these conditions. This targeted approach helps modulate the immune response with potential for improved disease control and reduced flare-ups.